These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3480885)

  • 21. Comparative in-vitro activity of five fluoroquinolones against mycobacteria.
    Davies S; Sparham PD; Spencer RC
    J Antimicrob Chemother; 1987 May; 19(5):605-9. PubMed ID: 3112094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of the 4-quinolones ciprofloxacin, pefloxacin and ofloxacin on the elimination of theophylline.
    Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL
    Pharm Weekbl Sci; 1987 Dec; 9 Suppl():S72-5. PubMed ID: 3481439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [In vitro antibacterial activity of new derivatives of pyridonecarboxylic acid, norfloxacin, ofloxacin, enoxacin and ciprofloxacin, against Vibrio cholerae O-1].
    Matsushita S; Yamada S; Kudoh Y; Ohashi M
    Kansenshogaku Zasshi; 1987 Mar; 61(3):292-6. PubMed ID: 3112282
    [No Abstract]   [Full Text] [Related]  

  • 25. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
    Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
    Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative in vitro studies with 4-quinolone antimicrobials.
    Felmingham D; O'Hare MD; Robbins MJ; Wall RA; Williams AH; Cremer AW; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(5):317-29. PubMed ID: 2941259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of the oxidative metabolism of theophylline in isolated rat hepatocytes by the quinolone antibiotic enoxacin and its metabolite oxoenoxacin, but not by ofloxacin.
    Mulder GJ; Nagelkerke JF; Tijdens RB; Wijnands WJ; Van der Mark EJ
    Biochem Pharmacol; 1988 Jul; 37(13):2565-8. PubMed ID: 3164618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of the 4-quinolones.
    Eggleston M; Park SY
    Infect Control; 1987 Mar; 8(3):119-25. PubMed ID: 3553053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Fluoroquinolones].
    Baykal M; Akalin E
    Mikrobiyol Bul; 1987 Apr; 21(2):151-7. PubMed ID: 3482120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia.
    Kemmerich B; Small GJ; Pennington JE
    Antimicrob Agents Chemother; 1986 Mar; 29(3):395-9. PubMed ID: 2940970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antichlamydial activity of quinolone carboxylic acids.
    Heppleston C; Richmond S; Bailey J
    J Antimicrob Chemother; 1985 May; 15(5):645-7. PubMed ID: 3159713
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
    Verbist L
    J Antimicrob Chemother; 1987 Sep; 20(3):363-72. PubMed ID: 3119552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Gyrase inhibitors modify metabolising processes in the liver].
    Staib AH; Harder S; Papenburg A; Stille W
    Dtsch Med Wochenschr; 1987 Oct; 112(44):1720-1. PubMed ID: 2822371
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical pharmacokinetics of the newer antibacterial 4-quinolones.
    Neuman M
    Clin Pharmacokinet; 1988 Feb; 14(2):96-121. PubMed ID: 3282749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The adverse effects of fluoroquinolones.
    Smith CR
    J Antimicrob Chemother; 1987 Jun; 19(6):709-11. PubMed ID: 3475267
    [No Abstract]   [Full Text] [Related]  

  • 36. The influence of quinolone derivatives on theophylline clearance.
    Wijnands WJ; Vree TB; van Herwaarden CL
    Br J Clin Pharmacol; 1986 Dec; 22(6):677-83. PubMed ID: 3567014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].
    Habiyaremye I; Verbist L; Vandepitte J
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):800-4. PubMed ID: 3116489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The action of quinolone carboxylic acids on Chlamydia trachomatis in vitro.
    Richmond SJ; Heppleston C; Bailey J
    Biochem Soc Trans; 1986 Apr; 14(2):503-4. PubMed ID: 2940134
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers.
    Chang T; Black A; Dunky A; Wolf R; Sedman A; Latts J; Welling PG
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():49-56. PubMed ID: 3162901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.